GÜNER AKGÜNER

Dr. GÜNER AKGÜNER

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GAGÜNER AKGÜNER
GÜNER AKGÜNER
MAMustafa Altınbaş
Mustafa Altınbaş
Background and objective: The CALLY index has been recognized as a prognostic biomarker across various malignancies; however, its prognostic utility in metastatic renal cell carcinoma (mRCC) has not been extensively characterized. This study aimed to elucidate the prognostic significance of the C-reactive protein–albumin–lymphocyte (CALLY) index in patients diagnosed with mRCC. Methods: In this retrospective multicenter study, patients with metastatic renal cell carcinoma were included. Demographic and disease-related data were collected. The CALLY index was calculated as follows: serum albumin level (g/dL) × absolute lymphocyte count (cells/µL)/C-reactive protein (CRP) (mg/dL) × 104. The optimal cut-off value for the CALLY index was determined using maximal log-rank analysis. Overall survival and progression-free survival analyses were performed according to the cut-off value, and Cox regression analyses were conducted to identify factors affecting prognosis. Results: A total of 95 patients were included in the present study. The prognostic cut-off value for the CALLY index was determined as 0.12. The median overall survival (OS) was 11.1 months (95% CI 6.7–15.4) in the CALLY index < 0.12 group, compared to 45.7 months (95% CI 31.6–59.8) in the CALLY index ≥ 0.12 group (p < 0.001). Similarly, the median progression-free survival (PFS) was 7.1 months (95% CI 4.5–13.2) in the CALLY index < 0.12 group and 33.1 months (95% CI 17.2–48.1) in the CALLY index ≥ 0.12 group (p < 0.001). In Cox regression analysis, a CALLY index < 0.12 was identified as an independent prognostic factor for shorter OS (HR: 0.41, 95% CI 0.22–0.76, p = 0.004) and PFS (HR: 0.40, 95% CI 0.23–0.69, p = 0.001). Conclusion: The CALLY index was identified as an independent prognostic biomarker in metastatic renal cell carcinoma. Prospective large-scale studies are needed to confirm its clinical utility.

1 January 2026 in TURKISH JOURNAL of CLINICS and LABORATORY
Verified
Journal Article
Closed access
GUGalip Uyar
Galip Uyar
GAGÜNER AKGÜNER
GÜNER AKGÜNER
KBKADRİYE BAŞKURT
KADRİYE BAŞKURT
ENES YEŞİLBAŞENES YEŞİLBAŞ
ENES YEŞİLBAŞ
SKSeher KAYA
Seher KAYA
GİGökşen İnanç İmamoğlu
Gökşen İnanç İmamoğlu
Background: Systemic inflammation and nutritional status are key determinants of prognosis in metastatic clear-cell renal carcinoma (mccRCC). Composite indices such as the Systemic Immune–Inflammation Index (SII) and the Modified Glasgow Prognostic Score (mGPS) have demonstrated prognostic relevance across cancers, but real-world data in mccRCC remain limited. Methods: This retrospective, single-center cohort included patients with histologically confirmed mccRCC who received first-line tyrosine kinase inhibitor (TKI) monotherapy (sunitinib, pazopanib, or cabozantinib) between November 2022 and November 2024 at Etlik City Hospital (Ankara, Türkiye). Associations between inflammatory–nutritional indices (SII, mGPS) and progression-free survival (PFS) were evaluated using Kaplan–Meier and multivariable logistic regression analyses. Results: A total of 55 patients met eligibility criteria and were included in the analysis. The median age was 62 years (IQR 52–71), and 67% were male. Median PFS was 13.24 months (95% CI 7.75–19.12), while median OS was not reached. High SII (≥ 870) was independently associated with shorter PFS in multivariable analysis (OR 5.05; 95% CI 1.14–15.77; p = 0.039). mGPS (1–2) was significantly associated with inferior PFS in Kaplan–Meier analysis (HR 3.43; 95% CI 1.42–8.30; p = 0.006; log-rank p = 0.001), but lost significance in multivariable modeling. Metformin use (OR 0.12; 95% CI 0.02–0.93; p = 0.044), sunitinib therapy (OR 0.07; 95% CI 0.006–0.74; p = 0.027), and favorable/intermediate IMDC risk group (OR 0.17; 95% CI 0.06–0.96; p = 0.047) were independently associated with a lower progression risk. Patients treated with cabozantinib (n = 15) showed a numerically longer median PFS (18.6 months; 95% CI 13.8–23.3) compared with sunitinib (n = 25, 12.2 months; 95% CI 5.5–19.0) and pazopanib (n = 15, 12.1 months; 95% CI 6.7–17.5), although this difference was not statistically significant (log-rank p = 0.152). Conclusion: In this real-world cohort of patients with mccRCC treated with first-line TKI, host-related inflammatory and nutritional status were closely associated with progression-free survival. Additionally, patients classified within the favorable IMDC risk group exhibited a significantly lower risk of progression, highlighting the importance of integrating clinical risk stratification with systemic inflammatory and nutritional markers. Incorporating such easily measurable biomarkers and clinical risk scores into existing prognostic models may enhance individualized risk assessment and therapeutic decision-making. Future prospective, multicenter, randomized controlled, and artificial intelligence–assisted studies are warranted to validate these findings and refine precision oncology approaches in this population.

11 March 2024
Verified
Book Chapter
Closed access
GAGÜNER AKGÜNER
GÜNER AKGÜNER
E vitamini kanserin gelişmesinde ve korunmasında araştırılan besinlerden biridir. Antioksidan özellikleri dokulardaki hücrelerin oksidatif stresten korunmasında rol oynar. Oksidatif stresin kanserdeki rolü nedeniyle diyetle alınan E vitamini tüketiminin kanseri önleme ve kanser tedavisindeki rolü üzerine birçok çalışma bulunmaktadır. Çalışmaların netliği ve sonuçlarının merkezinde, E vitamininin kanser üzerindeki olumlu etkisi belirsizliğini korumaktadır. Vitamin E is one of the nutrients researched in the development and protection of cancer. Its antioxidant properties play a role in protecting cells in tissues from oxidative stress. Due to the role of oxidative stress in cancer, there are many studies on the role of dietary vitamin E consumption in cancer prevention and cancer treatment. Central to the clarity and results of the studies, the positive effect of vitamin E on cancer remains unclear.

27 January 2026 in TURKISH JOURNAL of CLINICS and LABORATORY
Verified
Journal Article
Closed access
GAGÜNER AKGÜNER
GÜNER AKGÜNER
GUGalip Uyar
Galip Uyar
KBKADRİYE BAŞKURT
KADRİYE BAŞKURT
OSOsman Sutcuoglu
Osman Sutcuoglu
Amaç: Yaygın evre küçük hücreli akciğer kanseri (ES-SCLC), kötü prognozlu olup tedavisinde platin bazlı kemoterapi temel yaklaşımdır. Kemoterapinin yol açtığı nötropeni, febril nötropeni nedeniyle tedavi gecikmelerine ve hastaneye yatışlara neden olabilir. Granülosit koloni uyarıcı faktör (G-CSF) kullanımı, kemoterapiye bağlı nötropeni ve febril nötropeni insidansını azaltmaktadır. Bu çalışmanın amacı, ES-SCLC'de G-CSF kullanımının prognoz üzerindeki etkisini ve güvenilirliğini değerlendirmektir. Gereç ve Yöntemler: Bu tek merkezli, retrospektif çalışmaya 80 hasta dahil edilmiştir. Hastalar G-CSF kullanımına göre sınıflandırılmış ve genel sağkalım (OS) ile progresyonsuz sağkalım (PFS) gruplar arasında karşılaştırılmıştır. Prognoza etki eden faktörleri belirlemek amacıyla Cox regresyon modeli kullanılarak tek değişkenli ve çok değişkenli analizler yapılmıştır. G-CSF kullanımının güvenilirliği de değerlendirilmiştir. Bulgular: G-CSF grubunda medyan genel sağkalım (OS) 11,0 ay, G-CSF kullanılmayan grupta 8,6 aydı (p = 0,026). Medyan progresyonsuz sağkalım (PFS) G-CSF grubunda 8,0 ay, G-CSF kullanılmayan grupta 7,0 aydı (p = 0,044). Primer profilaksi grubunda medyan OS 15,1 ay, sekonder profilaksi grubunda ise 10,2 aydı (p = 0,099). Medyan PFS primer profilaksi grubunda 10,0 ay, sekonder profilaksi grubunda 7,4 aydı (p = 0,014). Multivariate analizde G-CSF kullanımı, daha uzun genel sağkalım (OS) (HR: 0,51; %95 CI: 0,28–0,90, p = 0,021) ve progresyonsuz sağkalım (PFS) (HR:0,57, %95 CI: 0,34-0,95, p = 0,031) için bağımsız bir prognostik faktör olarak tanımlandı. G-CSF kullanımına bağlı olarak 69 hastada (%86.3) herhangi bir advers olay gözlenmeyip, sadece 1 hastada (%1,3) ciddi (Grade 3) advers olay (trombositopeni) saptandı. Sonuç: Bu çalışmada, yaygın evre küçük hücreli akciğer kanseri (ES-SCLC) hastalarında G-CSF kullanımının genel sağkalımı iyileştirdiği bulunmuştur. Bu bulguları desteklemek için daha geniş ölçekli prospektif çalışmalara ihtiyaç duyulmaktadır.

7 August 2025
Verified
Book Chapter
Closed access
GAGÜNER AKGÜNER
GÜNER AKGÜNER
Kaposi Sarkomu (KS) endotel hücrelerinin multifokal malignitesi olup Kaposi Sarkomu ilişkili Herpesvirüs’le sıkı bir ilişkisi mevcuttur. AIDS ilişkili, endemik, klasik ve iyatrojenik ya da transplantasyon ilişkili dört tipi vardır. HIV(+) hastalarda HIV enfeksiyonunun yönetimi KS tedavisinde önemlidir. Lokal tedaviler, kemoterapi, immünoterapi gibi sistemik tedaviler, radyoterapi tedavide kullanılmaktadır. Hastaların takibinde anamnez, detaylı fizik muayene, laboratuvar testleri önemli olup, sistemik hastalık, progresif/refrakter hastalık varlığında takiplerde ek olarak radyolojik görüntüleme yöntemleri (X-RAY, BT, MRI, PET-BT) de kullanılmaktadır. HIV(+) vakalarda HIV tedavisinin yönetimi ve takibi KS tedavisinde önemlidir. Kaposi Sarcoma (KS) is a multifocal malignancy of endothelial cells and is strongly associated with Kaposi's Sarcoma-associated Herpesvirus (KSHV). There are four types of KS: AIDS-related, endemic, classic, and iatrogenic or transplant-associated. In HIV-positive patients, the management of HIV infection plays a critical role in the treatment of KS. Treatment modalities include local therapies, chemotherapy, immunotherapy, and radiotherapy. During patient follow-up, taking a detailed medical history, conducting thorough physical examinations, and performing laboratory tests are crucial. Additionally, in the presence of systemic or progressive/refractory disease, radiological imaging methods such as X-ray, CT, MRI, and PET-CT are also utilized. The management and monitoring of HIV treatment are essential components in the management of KS in HIV-positive patients.

6 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
HSHatice Ayyıldız Sevim
Hatice Ayyıldız Sevim
GUGalip Uyar
Galip Uyar
GAGÜNER AKGÜNER
GÜNER AKGÜNER
HŞHayriye Şahinli
Hayriye Şahinli
Background: The comparative prognostic value of the Endothelial Activation and Stress Index (EASIX) and the Inflammatory Prognostic Index (IPI) in extensive-stage small-cell lung cancer remains unclear. This study aimed to compare the prognostic value of EASIX and IPI and assess their contribution beyond established clinical factors. Methods: This retrospective single-center study included 129 patients with de novo extensive-stage small-cell lung cancer who initiated first-line systemic therapy between December 2022 and October 2025. Pretreatment EASIX and IPI values were analyzed as log2-transformed continuous variables in multivariable Cox models. Overall survival was the primary outcome, and first-line progression-free survival was the secondary outcome. Results: During a median follow-up of 26.91 months, 116 deaths and 123 progression-or-death events occurred. Each doubling of the EASIX value was independently associated with a higher hazard of death (adjusted hazard ratio, 1.14; 95% confidence interval, 1.01–1.28; p = 0.019), whereas IPI was not independently associated with overall survival. Neither index was independently associated with first-line progression-free survival. Adding EASIX to the clinical model improved model fit and increased the C-index from 0.619 to 0.650, whereas IPI provided no additional prognostic contribution. Conclusions: EASIX may provide prognostic information beyond established clinical factors for overall survival in extensive-stage small-cell lung cancer. These findings warrant validation in larger multicenter cohorts.